ReviewUrologie (Heidelberg, Germany)2026
[Artificial intelligence in the care of geriatric patients-more of a curse or more of a blessing?]
Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArtificial intelligence (AI) is conquering medicine in many fields. With geriatric patients, it is important not only to understand the decision tree of, for example, a tumor disease, but also to assess their functionality and functional deficits.
methodsFor potential (urological) care of geriatric patients, AI-supported tumor boards, AI-simulated human interaction, and AI-based polypharmacy tools were identified. The advantages and disadvantages, risks and benefits, and practical aspects are weighed against each other.
resultsThe specific characteristics of geriatric patients arise from their multidimensionality. These often involve functional impairments that can only be systematically assessed. The challenge will be to integrate these functional deficits, along with appropriate cut-offs, life expectancy, patient goals, anamnesis, and the potential risks of any therapy, into treatment decisions, in addition to the characteristics of a (tumor) disease. Ensuring the psychosocial care of nursing home residents during times of staff shortages also presents a challenge. "Learning" and "responsive" cuddly toys and robots could provide valuable support in this area. A third application of AI is certainly a comprehensive medication tool that compares multiple databases with the patient's specific needs.
conclusionAI applications in medicine and urology are inevitable. Their integration into the care of the particularly complex and vulnerable geriatric patient requires careful consideration: What information is needed regarding the patient, their illness, therapy, and therapy risks, and how can this information be applied? The question of whether AI is a curse or a blessing can perhaps currently be rephrased as "opportunities, but also risks."
Indexed as
Identifiers
42525286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.